Latham Biopharm Group — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Latham BioPharm Group is a private consulting firm serving the life sciences industry with deep expertise in product development and non-dilutive funding strategy. Leveraging a team of seasoned consultants with over 20 years of industry experience each, LBG acts as an extension of client teams to de-risk development and secure government grants. Its business model is purely service-based, offering strategic guidance rather than developing its own therapeutic pipeline. The company appears to be revenue-generating through its consulting engagements.

Drug DeliveryBiologics

Technology Platform

Human capital and methodological expertise in life sciences consulting, specializing in non-dilutive funding strategy, product development, and strategic planning. No proprietary therapeutic technology.

Opportunities

The growing complexity and capital needs of the biotech sector, especially in advanced modalities like cell and gene therapy, drive demand for specialized consulting.

The firm's strong focus on securing non-dilutive government funding is a major opportunity in a tight capital market, as clients seek to extend runways without dilution.

Risk Factors

Revenue is highly dependent on client R&D budgets, making it vulnerable to biotech funding cycles.

The business is also talent-dependent, risking brand erosion if key consultants depart.

Intense competition from both large consulting firms and niche boutiques pressures differentiation and pricing.

Competitive Landscape

LBG competes in the fragmented life sciences consulting market against large global management consultancies (e.g., McKinsey, IQVIA) and smaller boutique firms specializing in regulatory, CMC, or funding strategy. Its differentiation lies in its deep, senior-level industry experience and integrated service model combining strategic, development, and funding expertise.

More companies in United States →